Bicara executive exercises options, sells 12.5K shares
Bicara Therapeutics President and COO Ryan Cohlhepp reported an option exercise and related stock sales in Bicara Therapeutics Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bicara Therapeutics President and COO Ryan Cohlhepp reported an option exercise and related stock sales in Bicara Therapeutics Inc. common stock. He exercised stock options for 8,000 shares at an exercise price of $3.7898 per share, acquiring the same number of common shares.
On the same date, he sold a total of 12,500 common shares at a weighted average price of $23.0073 per share, executed in multiple transactions under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owns 196,141 common shares of Bicara Therapeutics Inc.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Cohlhepp Ryan
Role
President and COO
Sold
12,500 shs ($288K)
Approx. gross sale proceeds
$288K
Approx. exercise cost
$30K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 8,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,000 | $3.7898 | $30K |
| Sale | Common Stock | 8,000 | $23.0073 | $184K |
| Sale | Common Stock | 4,500 | $23.0073 | $104K |
Holdings After Transaction:
Stock Option (Right to Buy) — 109,334 contracts (Direct);
Common Stock — 196,141 shares (Direct)
Footnotes (3)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.58 to $23.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Options Exercised: 8,000 shares
Exercise Price: $3.7898 per share
Shares Sold: 12,500 shares
+5 more
8 metrics
Options Exercised
8,000 shares
Stock options converted into common stock on April 15, 2026
Exercise Price
$3.7898 per share
Exercise price for 8,000 stock options
Shares Sold
12,500 shares
Common stock sold in open-market transactions on April 15, 2026
Weighted Average Sale Price
$23.0073 per share
Weighted average for sales between $22.58 and $23.255
Shares Owned After Transactions
196,141 shares
Direct common stock holdings following April 15, 2026 trades
Remaining Options of This Grant
0
No remaining derivative position reported in derivativeSummary for this option
Option Expiration Date
August 8, 2033
Expiration date for the exercised stock option
10b5-1 Plan Adoption Date
February 12, 2025
Date the Rule 10b5-1 trading plan was adopted
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy, weighted average price, vest in sixteen equal quarterly installments, +1 more
5 terms
Rule 10b5-1 trading plan financial
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy financial
"security_title: Stock Option (Right to Buy)"
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vest in sixteen equal quarterly installments financial
"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023"
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transactions did Bicara Therapeutics (BCAX) executive Ryan Cohlhepp report?
Ryan Cohlhepp reported exercising options for 8,000 Bicara Therapeutics shares and selling 12,500 common shares. These transactions occurred on April 15, 2026 and combined an option exercise with open-market sales.
At what price did Ryan Cohlhepp exercise his Bicara Therapeutics (BCAX) stock options?
He exercised stock options at an exercise price of $3.7898 per share for 8,000 underlying Bicara Therapeutics common shares. These options were originally granted with vesting in sixteen equal quarterly installments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates